
Results from a multicenter phase 2 open-label study corroborate promising outcomes of a phase 1 trial showing the oncogene-targeted oral agent RG7204 as a promising treatment for metastatic melanoma (MM). Also known as PLX4032, RG7204 is being codeveloped by Genentech and Plexxikon. It acts to selectively inhibit oncogenic BRAF, a serine-threonine protein kinase that has been implicated in the pathogenesis of melanoma.
